Anti-obesity drugs

Area of Science:

• Pharmacology
• Obesity Research
• Metabolic Disease

Background:

• Global obesity rates are increasing, leading to preventable comorbidities like type 2 diabetes, hypertension, and cardiovascular disease.
• Lifestyle interventions alone are often insufficient for significant and sustained weight loss.
• There is a critical need for effective pharmacological interventions to aid weight management.

Purpose of the Study:

• To review recent advancements in pharmacological approaches for weight loss.
• To examine the efficacy and limitations of current and emerging weight-loss medications.
• To discuss safety profiles and generalizability of existing clinical trial data.

Main Methods:

• Review of recent studies on pharmacological weight-loss agents.
• Analysis of efficacy, safety, and side-effect profiles of specific drugs.
• Assessment of dropout rates and generalizability of trial findings.

Main Results:

• Liraglutide, lorcaserin, phentermine-topiramate, and bupropion-naltrexone demonstrate weight loss beyond placebo.
• Significant concerns exist regarding the safety and side-effect profiles of these agents.
• High dropout rates (up to 50% or more) were observed, primarily due to side effects.
• Trial data may lack generalizability due to the overrepresentation of women of European descent.

Conclusions:

• Current pharmacological interventions for weight loss have limitations, with side effects often overshadowing efficacy.
• Early substantial weight loss correlates with sustained weight loss, indicating a responsive phenotype.
• Future trials should focus on identifying specific patient subpopulations who are most likely to respond to these treatments.